| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| Age, years | 66 (±10) | 65 (±11) | 67 (±9) | 0.062 |
| Male sex (%) | 249 (73.2%) | 105 (75.0%) | 144 (72.0%) | 0.539 |
| Arterial hypertension (%) | 169 (49.7%) | 68 (50.4%) | 101 (49.2%) | 0.840 |
| Diabetes mellitus (%) | 65 (19.1%) | 29 (20.7%) | 36 (18.0%) | 0.531 |
| Dyslipidaemia (%) | 142 (42.5%) | 57 (41.6%) | 85 (43.1%) | 0.779 |
| Current smoker (%) | 48 (14.2%) | 18 (13.0%) | 30 (15.1%) | 0.142 |
| BMI, kg/m2 | 26.1 (±3.9) | 25.7 (±3.9) | 26.5 (±3.9) | 0.064 |
| Ischaemic aetiology (%) | 199 (58.5%) | 86 (61.4%) | 113 (56.5%) | 0.364 |
| PCI | 25 (7.4%) | 14 (10.0%) | 11 (5.5%) | 0.118 |
| CABG | 35 (10.3%) | 14 (10.0%) | 21 (10.5%) | 0.881 |
| QoL score | 31 (17–45) | 36 (20–51) | 26 (14–43) | 0.001 |
| 6MWT, metres | 331 (±111) | 320 (±108) | 340 (±112) | 0.138 |
| NYHA III-IV (%) | 236 (69.8%) | 107 (76.4%) | 129 (65.2%) | 0.026 |
| Sinus rhythm (%) | 233 (68.5%) | 89 (63.6%) | 144 (72.0%) | 0.218 |
| QRS duration, ms | 157 (±34) | 157 (±36) | 158 (±33) | 0.847 |
| Beta-blocker (%) | 250 (73.5%) | 101 (72.1%) | 149 (74.5%) | 0.628 |
| ACE-i/ARB (%) | 301 (88.5%) | 119 (85.0%) | 182 (91.0%) | 0.088 |
| MRA (%) | 147 (43.2%) | 63 (45.0%) | 84 (42.0%) | 0.583 |
| Diuretics (%) | 286 (84.1%) | 120 (85.7%) | 166 (83.0%) | 0.500 |
| Statin (%) | 197 (57.9%) | 79 (56.4%) | 118 (59.0%) | 0.636 |
| eGFR, mL/min/1.73 m2 | 63.2 (±22.7) | 62.6 (±24.8) | 63.7 (±21.2) | 0.667 |
| Haemoglobin, g/dL | 13.3 (±1.6) | 13.0 (±1.6) | 13.4 (±1.4) | 0.002 |
| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| Age, years | 66 (±10) | 65 (±11) | 67 (±9) | 0.062 |
| Male sex (%) | 249 (73.2%) | 105 (75.0%) | 144 (72.0%) | 0.539 |
| Arterial hypertension (%) | 169 (49.7%) | 68 (50.4%) | 101 (49.2%) | 0.840 |
| Diabetes mellitus (%) | 65 (19.1%) | 29 (20.7%) | 36 (18.0%) | 0.531 |
| Dyslipidaemia (%) | 142 (42.5%) | 57 (41.6%) | 85 (43.1%) | 0.779 |
| Current smoker (%) | 48 (14.2%) | 18 (13.0%) | 30 (15.1%) | 0.142 |
| BMI, kg/m2 | 26.1 (±3.9) | 25.7 (±3.9) | 26.5 (±3.9) | 0.064 |
| Ischaemic aetiology (%) | 199 (58.5%) | 86 (61.4%) | 113 (56.5%) | 0.364 |
| PCI | 25 (7.4%) | 14 (10.0%) | 11 (5.5%) | 0.118 |
| CABG | 35 (10.3%) | 14 (10.0%) | 21 (10.5%) | 0.881 |
| QoL score | 31 (17–45) | 36 (20–51) | 26 (14–43) | 0.001 |
| 6MWT, metres | 331 (±111) | 320 (±108) | 340 (±112) | 0.138 |
| NYHA III-IV (%) | 236 (69.8%) | 107 (76.4%) | 129 (65.2%) | 0.026 |
| Sinus rhythm (%) | 233 (68.5%) | 89 (63.6%) | 144 (72.0%) | 0.218 |
| QRS duration, ms | 157 (±34) | 157 (±36) | 158 (±33) | 0.847 |
| Beta-blocker (%) | 250 (73.5%) | 101 (72.1%) | 149 (74.5%) | 0.628 |
| ACE-i/ARB (%) | 301 (88.5%) | 119 (85.0%) | 182 (91.0%) | 0.088 |
| MRA (%) | 147 (43.2%) | 63 (45.0%) | 84 (42.0%) | 0.583 |
| Diuretics (%) | 286 (84.1%) | 120 (85.7%) | 166 (83.0%) | 0.500 |
| Statin (%) | 197 (57.9%) | 79 (56.4%) | 118 (59.0%) | 0.636 |
| eGFR, mL/min/1.73 m2 | 63.2 (±22.7) | 62.6 (±24.8) | 63.7 (±21.2) | 0.667 |
| Haemoglobin, g/dL | 13.3 (±1.6) | 13.0 (±1.6) | 13.4 (±1.4) | 0.002 |
Values are presented as mean ± SD, median (IQR), or n (%). Values in bold have a P-value < 0.05.
ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; MWT, minute walking test; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; QoL, quality of life.
| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| Age, years | 66 (±10) | 65 (±11) | 67 (±9) | 0.062 |
| Male sex (%) | 249 (73.2%) | 105 (75.0%) | 144 (72.0%) | 0.539 |
| Arterial hypertension (%) | 169 (49.7%) | 68 (50.4%) | 101 (49.2%) | 0.840 |
| Diabetes mellitus (%) | 65 (19.1%) | 29 (20.7%) | 36 (18.0%) | 0.531 |
| Dyslipidaemia (%) | 142 (42.5%) | 57 (41.6%) | 85 (43.1%) | 0.779 |
| Current smoker (%) | 48 (14.2%) | 18 (13.0%) | 30 (15.1%) | 0.142 |
| BMI, kg/m2 | 26.1 (±3.9) | 25.7 (±3.9) | 26.5 (±3.9) | 0.064 |
| Ischaemic aetiology (%) | 199 (58.5%) | 86 (61.4%) | 113 (56.5%) | 0.364 |
| PCI | 25 (7.4%) | 14 (10.0%) | 11 (5.5%) | 0.118 |
| CABG | 35 (10.3%) | 14 (10.0%) | 21 (10.5%) | 0.881 |
| QoL score | 31 (17–45) | 36 (20–51) | 26 (14–43) | 0.001 |
| 6MWT, metres | 331 (±111) | 320 (±108) | 340 (±112) | 0.138 |
| NYHA III-IV (%) | 236 (69.8%) | 107 (76.4%) | 129 (65.2%) | 0.026 |
| Sinus rhythm (%) | 233 (68.5%) | 89 (63.6%) | 144 (72.0%) | 0.218 |
| QRS duration, ms | 157 (±34) | 157 (±36) | 158 (±33) | 0.847 |
| Beta-blocker (%) | 250 (73.5%) | 101 (72.1%) | 149 (74.5%) | 0.628 |
| ACE-i/ARB (%) | 301 (88.5%) | 119 (85.0%) | 182 (91.0%) | 0.088 |
| MRA (%) | 147 (43.2%) | 63 (45.0%) | 84 (42.0%) | 0.583 |
| Diuretics (%) | 286 (84.1%) | 120 (85.7%) | 166 (83.0%) | 0.500 |
| Statin (%) | 197 (57.9%) | 79 (56.4%) | 118 (59.0%) | 0.636 |
| eGFR, mL/min/1.73 m2 | 63.2 (±22.7) | 62.6 (±24.8) | 63.7 (±21.2) | 0.667 |
| Haemoglobin, g/dL | 13.3 (±1.6) | 13.0 (±1.6) | 13.4 (±1.4) | 0.002 |
| . | Overall population (N = 340) . | MR non-improvers (N = 140) . | MR improvers (N = 200) . | P- value . |
|---|---|---|---|---|
| Age, years | 66 (±10) | 65 (±11) | 67 (±9) | 0.062 |
| Male sex (%) | 249 (73.2%) | 105 (75.0%) | 144 (72.0%) | 0.539 |
| Arterial hypertension (%) | 169 (49.7%) | 68 (50.4%) | 101 (49.2%) | 0.840 |
| Diabetes mellitus (%) | 65 (19.1%) | 29 (20.7%) | 36 (18.0%) | 0.531 |
| Dyslipidaemia (%) | 142 (42.5%) | 57 (41.6%) | 85 (43.1%) | 0.779 |
| Current smoker (%) | 48 (14.2%) | 18 (13.0%) | 30 (15.1%) | 0.142 |
| BMI, kg/m2 | 26.1 (±3.9) | 25.7 (±3.9) | 26.5 (±3.9) | 0.064 |
| Ischaemic aetiology (%) | 199 (58.5%) | 86 (61.4%) | 113 (56.5%) | 0.364 |
| PCI | 25 (7.4%) | 14 (10.0%) | 11 (5.5%) | 0.118 |
| CABG | 35 (10.3%) | 14 (10.0%) | 21 (10.5%) | 0.881 |
| QoL score | 31 (17–45) | 36 (20–51) | 26 (14–43) | 0.001 |
| 6MWT, metres | 331 (±111) | 320 (±108) | 340 (±112) | 0.138 |
| NYHA III-IV (%) | 236 (69.8%) | 107 (76.4%) | 129 (65.2%) | 0.026 |
| Sinus rhythm (%) | 233 (68.5%) | 89 (63.6%) | 144 (72.0%) | 0.218 |
| QRS duration, ms | 157 (±34) | 157 (±36) | 158 (±33) | 0.847 |
| Beta-blocker (%) | 250 (73.5%) | 101 (72.1%) | 149 (74.5%) | 0.628 |
| ACE-i/ARB (%) | 301 (88.5%) | 119 (85.0%) | 182 (91.0%) | 0.088 |
| MRA (%) | 147 (43.2%) | 63 (45.0%) | 84 (42.0%) | 0.583 |
| Diuretics (%) | 286 (84.1%) | 120 (85.7%) | 166 (83.0%) | 0.500 |
| Statin (%) | 197 (57.9%) | 79 (56.4%) | 118 (59.0%) | 0.636 |
| eGFR, mL/min/1.73 m2 | 63.2 (±22.7) | 62.6 (±24.8) | 63.7 (±21.2) | 0.667 |
| Haemoglobin, g/dL | 13.3 (±1.6) | 13.0 (±1.6) | 13.4 (±1.4) | 0.002 |
Values are presented as mean ± SD, median (IQR), or n (%). Values in bold have a P-value < 0.05.
ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; MWT, minute walking test; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; QoL, quality of life.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
